natgillin/translations-raw huggingface dataset:
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment. 
Prethodno liječenje s drugim protuupalnim tvarima može rezultirati dodatnim ili pojačanim neželjenim popratnim pojavama te takvo liječenje treba prekinuti najmanje 24 sata prije liječenja Meloxidylom.
When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment. 
Kada se veterinarsko-medicinski proizvod koristi u propisanim količinama, ustaljenost koncentracije u plazmi postiže se drugog dana liječenja.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine. 
Oko 75% aplicirane doze eliminira se putem izmeta dok se ostatak izlučuje mokraćom.
For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. 
Za smanjenje simptoma šepavosti i upale pri neinfektivnim lokomotornim poremećajima.
Meloxicam is eliminated with a half-life of 24 hours. 
Poluvrijeme eliminacije meloksikama iz organizma je 24 sata.
PHARMACOLOGICAL PROPERTIES 
FARMAKODINAMIČKA SVOJSTVA
In horses, a transient swelling at the injection site can occur but resolves without intervention. 
U konja se na mjestu davanja može javiti manja prolazna oteklina koja se spontano povuče bez liječenja.
PACKAGE LEAFLET: Meloxidyl 1.5 mg/ml oral suspension for dogs 10, 32 & 100 ml 
UPUTA O VMP Meloxidyl 1,5 mg/ml peroralna suspenzija za pse 10 ml, 32 ml i 100 ml
Meloxicam 20 mg 
Meloksikam 20 mg
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. 
Pri istovremenoj primjeni s drugim NSPUL, diureticima, antikoagulansima, aminoglikozidnim antibioticima i tvarima koje se u visokom postotku vežu na proteine, može zbog kompetitivnog učinka doći do toksičnog djelovanja.
Muscle Liver Kidney Milk 
Meso Mišići Jetra Bubrezi
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e)) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na10.000 tretiranih životinja) - vrlo rijetke (manje od 1 životinje na 10.000 tretiranih životinja, uključujući izolirane slučajeve).
For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. 
Za ublažavanje kliničkih znakova pri akutnim respiratornim infekcijama, uz odgovarajuću antibiotsku terapiju.
Meloxicam Meloxicam 
Meloksikam Meloksikam
Solution for injection. 
OBLIK Injekcijska otopina.
Dogs: IV or SC Cats: SC 
PUT(EVI) PRIMJENE Psi: i.v. ili s.c.
Approximately 97 % of meloxicam is bound to plasma proteins. 
Oko 97 % meloksikama veže se uz proteine plazme.
More than 97 % of meloxicam is bound to plasma proteins. 
Više od 97 % meloksikama veže se uz proteine plazme.
Do not administer concurrently with glucocorticosteroids, other non-steroidal anti-inflammatory drugs or with anti-coagulant agents. 
Ne koristiti istovremeno s glukokortikosteroidima, drugim NSPUL ili s antikoagulansima.
In cattle, meloxicam is also a major excretion product in milk and bile whereas urine contains only traces of the parent compound. 
U goveda, meloksikam se većinom izlučuje kroz mlijeko i žuć dok se u mokraći nalazi samo u tragovima.
A clinical response is normally seen within 7 days. 
Klinički učinak uočljiv je unutar 7 dana od početka liječenja.
- Do not use in cats less than 6 weeks of age. 
Ne koristiti u mačaka mlađih od 6 tjedana.
In case of overdose, adverse reactions, as listed in Section 4.6, are expected to be more severe and more frequent. 
U slučaju predoziranja popratne reakcije opisane u dijelu 4.6 znatno su izraženije i učestalije te je potrebno primijeniti simptomatsku terapiju.
Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. 
Ne koristiti u životinja s gastrointestinalnim poremećajima, kao što su iritacije i krvarenja, smanjenom funkcijom jetre, srca ili bubrega te hemoragijskim poremećajima.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 
S neiskorištenim veterinarsko - medicinskim proizvodom i praznom ambalažom postupa se u skladu s lokalnim propisima.
Meloxidyl must not be administered in conjunction with other NSAIDs or glucocorticosteroids. 
Meloxydil se ne smije primjenjivati istodobno s drugim NSPUL ili glukokortikosteroidima.
Post-operative pain and inflammation following surgical procedures: After initial treatment with meloxicam 2 mg/ml solution for injection for cats, continue treatment 24 hours later with Meloxidyl 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg bodyweight. 
Nakon početnog jednokratnog parenteralnog davanja meloksikama 2 mg/ml injekcijske otopine za mačke, liječenje se nastavlja nakon 24 sata davanjem Meloxidyl 0,5 mg/ml peroralne suspenzije za mačke u dozi od 0,05 mg meloksikama/kg tjelesne mase.
A clinical response is normally seen within 3 - 4 days. 
Klinički učinak uočljiv je 3 - 4 dana od početka liječenja.
Meloxicam also has anti-endotoxic properties because it has been shown to inhibit production of thromboxane B2 induced by E. coli endotoxin administration in calves, lactating cows and pigs. 
Meloksikam ima i anti - endotoksična svojstva jer se pokazalo da inhibira stvaranje tromboksana B2 izazvano unosom endotksina E.
One ml contains: 
SASTAV DJELATNIH TVARI 1 ml sadržava:
EXP: 
ROK VALJANOSTI EXP:
Veterinary medicinal product subject to prescription. 
Veterinarsko-medicinski proizvod je potrebno pažljivo dozirati.
For the relief of post-operative pain following dehorning in calves. 
Za ublažavanje postoperacijskih bolova nakon odrožnjavanja teladi.
Attach the dosing syringe to the bottle by gently pushing the end onto the top of the bottle. 
Namjestite brizgalicu na otvor bočice uz lagani pritisak
Oral use. 
Za peroralno davanje.
Cardboard box containing 5 ml glass bottle with one measuring syringe. 
Kartonska kutija sa staklenom bočicom od 5 ml te jednom graduiranom brizgalicom.
In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies. 
U kliničkim pokusima, manja prolazna oteklina na mjestu uboda pri subkutanom davanju primijećena je u manje od 10 % liječenih goveda.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. 
Ukoliko se jave nuspojave, liječenje treba prekinuti i potražiti savjet veterinara.
EXP Once opened, use within 6 months. 
Jednom otvoren upotrijebiti do 6 mjeseci.
Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non steroids. 
Farmakoterapijska grupa: nesteroidni protuupalni i antireumatski pripravci.
Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. 
Ublažavanje post operativnih bolova i upala nakon ortopedskih kirurških zahvata i operacija mekih tkiva).
Silica colloidal anhydrous Sorbitol liquid non-crystallising Glycerol, xylitol Sodium benzoate Citric acid anhydrous Purified water. 
Ksantanska guma Silicijev dioksid koloidni bezvodni Sorbitol, tekući nekristalizirajući Glicerol
Do not use in dogs less than 6 weeks of age. 
Ne koristiti u pasa mlađih od 6 tjedana.
32 ml bottle in a cardboard box 
Bočice od 32 ml u kartonskoj kutiji
PACKAGE LEAFLET: Meloxidyl 20 mg/ml solution for injection for cattle, pigs, horses 50, 100, & 250 ml 
UPUTA O VMP Meloxidyl 20 mg/ml, injekcijska otopina za goveda svinje i konje 50 ml, 100 ml i 250 ml
10 ml bottle in a cardboard box 
Bočice od 10 ml u kartonskoj kutiji
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) 
Učestalost nuspojava je određena sukladno sljedećim pravilima: - vrlo česte (više od 1 na 10 tretiranih životinja pokazuju nuspojavu(e)) - česte (više od 1 ali manje od 10 životinja na 100 tretiranih životinja) - manje česte (više od 1 ali manje od 10 životinja na 1.000 tretiranih životinja) - rijetke (više od 1 ali manje od 10 životinja na10.000 tretiranih životinja)
Cardboard box containing 15 ml high density polyethylene bottle with one measuring syringe. 
Kartonska kutija s bočicom od polietilena visoke gustoće od 15 ml te jednom graduiranom brizgalicom.
Meloxicam 5 mg/ml Excipients: Ethanol 150 mg/ml 
Meloksikam 5 mg/ml Pomoćna tvar: Etanol 150 mg/ml
Following subcutaneous administration, meloxicam is completely bioavailable and maximal mean plasma concentrations of 0.73 μg/ml in dogs and 1.1 μg/ml in cats were reached approximately 2.5 hours and 1.5 hours post administration, respectively. 
Po subkutanom davanju meloksikam je u cijelosti bioraspoloživ te prosječno kod pasa za približno 2.5 sata postiže vršnu koncentraciju u plazmi od 0,73 μg/ml, dok kod mačaka za približno 1.5 sat postiže vršnu koncentraciju od 1,1 μg/ml.
Shelf life after first opening the container: 6 months. 
Rok valjanosti poslije prvog otvaranja spremnika: 6 mjeseci.
Meloxidyl 1.5 mg/ml - Meloxidyl 5 mg/ml - Meloxidyl 0.5 mg/ml Not applicable 
Za Meloxidyl 1,5 mg/ml, Meloxidyl 5 mg/ml, Meloxidyl 0,5 mg/ml:
Method and route of administration 
Načini i put primjene
Ethanol, anhydrous Poloxamer 188 
Poloksamer 188
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box of 10 ml vial 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU Kartonska kutija za bočicu od 10 ml
Solution for injection Clear, colourless to yellowish solution. 
Bistra, bezbojna do žućkasta otopina.
Meloxidyl 1.5 mg/ml oral suspension may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection. 
U nastavku liječenja može se koristiti Meloxidyl 1,5 mg/ml peroralna suspenzija u dozi od 0,1 mg meloksikama/kg tjelesne mase, 24 sata nakon davanja injekcije.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box of 15 ml vial 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU Kartonska kutija za bočicu od 15 ml
Turn the bottle and syringe upside down. 
Okrenite spojenu bočicu brizgalicu.
100 ml bottle in a cardboard box 
Bočice od 100 ml u kartonskoj kutiji
Concurrent administration of potential nephrotoxic drugs should be avoided. 
Potrebno je izbjegavati istodobnu primjenu s drugim potencijalno nefrotoksičnim veterinarsko-medicinskim proizvodima.
One ml contains: Meloxicam 
1 ml sadržava: Meloksikam
Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg body weight) before surgery, for example at the time of induction of anaesthesia. 
Jednokratno subkutano davanje u dozi od 0,3 mg meloksikama/kg tjelesne mase (odnosno 0,06 ml/kg tjelesne mase) prije kirurškog zahvata, primjerice pri uvođenju u anesteziju.
These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. 
One se uglavnom javljaju u prvom tjednu liječenja, većinom su prolazne naravi te se spontano povuku po prestanku terapije.
Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent. 
Ukoliko se kliničko stanje ne popravi, liječenje treba prekinuti najkasnije za 14 dana.
• If side effects occur, treatment should be discontinued and the advice of a veterinarian should be sought. 
• Ukoliko se primijete nuspojave, liječenje treba prekinuti i potražiti savjet veterinara.
Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight) before surgery, for example at the time of induction of anaesthesia. 
Jednokratno intravenozno ili subkutano davanje u dozi od 0,2 mg meloksikama/kg tjelesne mase (odnosno 0,4 ml/10 kg tjelesne mase) prije kirurškog zahvata, primjerice pri uvođenju u anesteziju.
Musculo-skeletal disorders: 
Mišićno - koštani poremećaji:
Name and address of the manufacturers responsible for batch release 
Naziv i adresa proizvođača odgovornog(ih) za puštanje serije u promet:
Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent. 
Ukoliko se kliničko stanje ne popravi, liječenje treba prekinuti najkasnije za 10 dana.
Excipients 
NUSPOJAVE
• People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. 
• Osobe preosjetljive na nesteroidne protuupalne NSPUL trebaju izbjegavati kontakt s ovim veterinarsko - medicinskim proizvodom.
The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). 
Brizgalica odgovara otvoru na boci, a naznačena gradacija odgovara dozi održavanja (tj. 0,1 mg/meloksikama /kg tjelesne mase).
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. 
Nastavlja se dnevnim (u razmacima od 24 sata) peroralnim davanjem održavajuće doze od 0,1 mg meloksikama/kg tjelesne mase.
Label of 250 ml vial 
Etiketa bočice od 250 ml
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Label of 100 ml vial 
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKOVANJU Etiketa bočice od 100 ml
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after EXP. 
Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na kartonskoj kutiji i bočici poslije EXP.
Single subcutaneous or intravenous injection at a dosage of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight) in combination with antibiotic therapy or with oral re-hydration therapy, as appropriate. 
Jednokratno subkutano ili intravenozno davanje u dozi od 0,5 mg meloksikama/kg tjelesne mase (tj. 2,5 ml/100 kg tjelesne mase), po potrebi u kombinaciji s antibiotskim liječenjem ili peroralnom rehidracijom.
Cardboard box of 5 ml vial 
Kartonska kutija za bočicu od 5 ml
Special precautions for storage 
Posebne mjere opreza pri čuvanju
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight. 
Nastavlja se dnevnim (u razmacima od 24 sata) peroralnim davanjem održavajuće doze od 0,05 mg meloksikama/kg tjelesne mase.
PACKAGE LEAFLET: Meloxidyl 0.5 mg/ml oral suspension for cats 15 & 5 ml 
UPUTA O VMP Meloxidyl 0,5 mg/ml peroralna otopina za mačke 15 ml i 5 ml
Meloxidyl 20 mg/ml solution for injection for cattle, pigs and horses 
Meloxidyl 20 mg/ml, injekcijska otopina za goveda, svinje i konje.
Solution for injection 
OBLIK Injekcijska otopina
Meloxidyl 1.5 mg/ml oral suspension for dogs. 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Meloxidyl 1,5 mg/ml peroralna suspenzija za pse.
People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. 
Osobe preosjetljive na nesteroidne protuupalne lijekove (NSPUL) trebaju izbjegavati kontakt s ovim veterinarsko - medicinskim proizvodom.
These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. 
Vrlo rijetko ove nuspojave mogu biti ozbiljne naravi ili fatalne.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. 
Liječenje započinje jednokratnom dozom od 0,2 mg meloksikama/kg tjelesne mase prvog dana.
The product must not be administered in conjunction with other NSAIDs or glucocorticosteroids. 
Ovaj veterinarsko-medicinski proizvod ne smije se primjenjivati istodobno s drugim NSPUL ili glukokortikosteroidima.
Meloxidyl 1.5 mg/ml oral suspension for dogs may be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg body weight, 24 hours after administration of the injection. 
U nastavku liječenja može se koristiti Meloxidyl 1,5 mg /ml peroralna suspenzija za pse u dozi od mg meloksikama/kg tjelesne mase, 24 sata po davanju injekcije.
Push down and unscrew bottle top. 
Čep prije odvrtanja pritisnite prema dolje.
Cardboard box of 32 ml vial 
Kartonska kutija za bočicu od 32 ml
Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, non-steroids (oxicams) ATC-vet code: QM01AC06 
Farmakoterapijska grupa: nesteroidni protuupalni i antireumatski veterinarsko-medicinski proizvodi (oksikami).
Meloxidyl 0.5 mg/ml 
Meloksikam 0,5 mg
To be administered mixed with food. 
Veterinarsko-medicinski proizvod se daje se umiješan u hrani.
Cats: single administration of 0.3 mg meloxicam/kg body weight (i.e. 0.06 ml/kg). 
Mačke: jednokratno davanje 0,3 mg meloksikama/kg tjelesne mase (tj. 0,06 ml/kg).
Z.I. 
A.
Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg body weight). 
Jednokratno subkutano davanje u dozi od 0,2 mg meloksikama/kg tjelesne mase (odnosno 0,4 ml/10 kg tjelesne mase).
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day. 
Liječenje započinje jednokratnom dozom od 0.1 mg meloksikama/kg tjelesne mase prvog dana.
Single intravenous injection at a dosage of 0.6 mg meloxicam/kg body weight (i.e. 3.0 ml/100 kg body weight). 
Jednokratno intravensko davanje u dozi od 0,6 mg meloksikama/kg tjelesne mase (tj. 3,0 ml/100 kg tjelesne mase).
Cardboard box of 100 ml vial 
Kartonska kutija za bočicu od 100 ml
PACKAGE LEAFLET: Meloxidyl 5 mg/ml solution for injection for dogs, cats 10 ml 
UPUTA O VMP Meloxidyl 5 mg/ml, injekcijska otopina za pse i mačke 10 ml
Single intramuscular injection at a dosage of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/100 kg body weight) in combination with antibiotic therapy, as appropriate. 
Jednokratno intramuskularno davanje u dozi od 0,4 mg meloksikama/kg tjelesne mase (tj. 2,0 ml/ 100 kg tjelesne mase u kombinaciji s odgovarajućim antibiotskim liječenjem.
Meat and offal: 5 days 
Svinje: Meso i iznutrice: 5 dana
1 ml contains 1.5 mg of meloxicam 
SASTAV DJELATNIH TVARI 1 ml sadržava: 1,5 mg meloksikama
Typical adverse reactions of Non Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. 
Povremeno se mogu javiti nuspojave karakteristične za nesteroidne protuupalne veterinarskomedicinske proizvode (NSPUL), poput gubitka apetita, povraćanja, proljeva, pojave krvi u izmetu te apatije.
Meloxidyl 5 mg/ml 
Meloksikam 5 mg
Avoid use in very severely dehydrated, hypovolaemic or hypotensive animals which require parenteral rehydration, as there may be a potential risk of renal toxicity. 
Zbog povećanog rizika toksičnog oštećenja bubrega, korištenje veterinarsko-medicinskog proizvoda treba izbjegavati kod dehidriranih i hipovolemičnih životinja te životinja s hipotenzijom, koje trebaju parenteralnu rehidraciju.
Post-operative pain and inflammation following surgical procedures: In case additional pain relief is required, multimodal pain therapy should be considered. 
U slučaju potrebe za korištenjem dodatnih veterinarsko-medicinskih proizvoda za ublažavanje bolova treba razmotriti primjenu multimodalne terapije.
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. 
Meloksikam je nesteroidni protuupalni veterinarsko-medicinski proizvod (NSPUL) iz klase oksikama čije se djelovanje temelji na inhibiciji sinteze prostaglandina, što dovodi do protuupalnog, analgetskog, antieksudativnog antipiretičkog učinka.
Each ml contains: - 1.5 mg of meloxicam - 2 mg of sodium benzoate 
1 ml peroralne suspenzije za pse sadržava: 1,5 mg meloksikama, 2 mg natrijeva benzoata.
Dogs: single administration of 0.2 mg meloxicam/kg body weight (i.e. 0.4 ml/10 kg). 
Psi: jednokratno davanje 0,2 mg meloksikama/kg tjelesne mase (tj. 0,4 ml/10 kg).
Excipient: 
Karencija:
Meloxicam 20 mg/ml Excipients: Ethanol anhydrous 150 mg/ml Clear, colourless to yellowish solution. 
Meloksikam 20 mg/ml Pomoćna tvar: Bezvodni etanol 150 mg/ml
Meloxidyl 1.5 mg/ml oral suspension for dogs 
NAZIV VETERINARSKO - MEDICINSKOG PROIZVODA Meloxidyl 1,5 mg/ml, peroralna suspenzija za pse
Material of the primary container 
Materijali unutarnjeg pakiranja:
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. 
Povremeno se mogu javiti nuspojave karakteristične za NSPUL, poput gubitka apetita, povraćanja, proljeva, pojave krvi u izmetu,apatije i zatajenja bubrega.
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. 
Ublažavanje upale i bolova pri akutnim i kroničnim mišićno - koštanim poremećajima u pasa.
1 ml contains 20 mg of meloxicam. 
SASTAV DJELATNIH TVARI 1 ml sadržava: meloksikam 20 mg
For use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders. 
Za ublažavanje upale i olakšavanje bolova pri akutnim i kroničnim mišićno koštanim poremećajima.
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. 
Osobe preosjetljive na NSPUL trebaju izbjegavati kontakt s ovim veterinarsko - medicinskim proizvodom.
INDICATION(S) Cattle: 
PUT(EVI) PRIMJENE Goveda: s.c. ili i.v.
• Avoid use in any dehydrated, hypovolaemic or hypotensive animal, if there is a potential risk of increased renal toxicity. 
• Zbog povećanog rizika toksičnog oštećenja bubrega, korištenje veterinarsko-medicinskog proizvoda treba izbjegavati kod dehidriranih i hipovolemičnih životinja te životinja s hipotenzijom.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Dosage for each species 
DOZIRANJE ZA SVAKU CILJNU VRSTU ŽIVOTINJA, NAČIN I PUTEVI PRIMJENE
Type III glass bottle with high density polyethylene tamper evidence screw cap. Low density polyethylene syringe insert for the polypropylene measuring syringe. 
Bočica od stakla tipa III sa sigurnosnim navojnim zatvaračem od polietilena visoke gustoće.
Alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats. 
Ublažavanje upale i bolova pri akutnim i kroničnim mišićno koštanim poremećajima u mačaka.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation (See section 4.3). 
4.7 Primjena tijekom graviditeta, laktacije ili nesenja Neškodljivost veterinarsko - medicinskog proizvoda nije praćena tijekom graviditeta i laktacije (vidi
• In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. 
• Pri slučajnom gutanju veterinarsko-medicinskog proizvoda potrebno je odmah potražiti liječnički savjet uz predočenje upute za korištenje.
Meloxidyl in conjunction with other NSAIDs or glucocorticosteroids. 
NSPUL ili glukokortikosteroidima.
Liver Kidney 
Meso Jetra Bubrezi
Meloxidyl 20 mg/ml 
KOLIČINA DJELATNE(IH) TVARI Meloksikam 20 mg/ml
Label of 100 ml vial 
VELIČINA PAKOVANJA 100 ml